Molecular Biosystems successfully completes Phase I trials for ORALEX, the company's orally administered ultrasound imaging agent.SAN DIEGO--(BUSINESS WIRE)--May 25, 1995--Molecular Biosystems Inc. (NYSE NYSE See: New York Stock Exchange :MB) Thursday announced the completion of Phase I clinical trials for ORALEX, the company's proprietary orally administered ultrasound imaging agent. ORALEX successfully enhanced abdominal images and demonstrated no significant safety problems. ORALEX was shown to be more effective than the control, water, which is the only agent currently used to improve abdominal imaging. ORALEX facilitated the displacement of gas in the stomach and provided an acoustic window which enhanced the ability to visualize the pancreas and stomach wall. It was also effective in slowing the gastric emptying process, allowing increased time of visualization for clinicians. Phase II trials are planned for summer 1995, pending the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review of the Phase I results. "ORALEX provided an acoustically clear `window' through the stomach in order to view the surrounding abdominal organs, including the stomach, pancreas, small intestine small intestine Long, narrow, convoluted tube in which most digestion takes place. It extends 22–25 ft (6.7–7.6 m), from the stomach to the large intestine. and gallbladder. The results of this trial are an important step in the clinical development of ORALEX," said Kenneth J. Widder, M.D., chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . Molecular Biosystems, based in San Diego, is a leader in the development of ultrasound contrast agents for medical imaging. In August 1994, MBI MBI Management Buy-In MBI Moody Bible Institute MBI Mathematical Biosciences Institute MBI Modular Building Institute MBI Mechanical Breakdown Insurance MBI Molecular Biology Institute MBI Maslach Burnout Inventory (psychometrics) received final approval from the U.S. Food and Drug Administration to begin domestic marketing of ALBUNEX, MBI's flagship ultrasound contrast agent. ALBUNEX is currently marketed in Japan by Shionogi & Co. Ltd., and in the United States by Mallinckrodt Medical Inc. (Mallinckrodt Group Inc. NYSE:MKG MkG Mit Kameradschaftlichen Grüßen (German: With Best Regards) MKG Mitsubishi Kreditbank GMBH (German branch of Mitsubishi Bank) MKG Muskegon, MI, USA - Muskegon County International Airport ). Hafslund Nycomed AS (NYSE:HN) will market ALBUNEX in Europe. CONTACT: Molecular Biosystems Inc., San Diego Gerard A. Wills/Stephen F. Keane 619/452-0681, ext. 2212 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion